Europe Biotech & Life Sciences Reservations open Page created Nov 16, 2026

List of Biotech Companies with EMA PRIME Designation

Sponsors of medicines that the European Medicines Agency judged eligible for its PRIME (PRIority MEdicines) scheme, joined with product, therapeutic area, indication, development stage and headquarters country, for BD, licensing, investment and CRO/CDMO teams extending an FDA Breakthrough Therapy target list to Europe.

Fields we plan to include

Company
Product (INN or code)
PRIME indication
Therapeutic area
Date PRIME eligibility granted
Substance type (ATMP, biological, chemical)
EMA applicant type (SME / other / academic)
PRIME status (current or left scheme)
Headquarters country
Company website
Also FDA Breakthrough Therapy
Source announcement URL

Data Preview

* Free sample rows, unverified and may contain errors. This list isn't for sale yet.
CompanyProductPRIME indicationAnnounced
Neurona TherapeuticsSourceNRTX-1001Drug-resistant focal epilepsy (adults)November 5, 2025
Electra TherapeuticsSourceELA026Secondary hemophagocytic lymphohistiocytosis (sHLH)October 22, 2025
Endeavor BioMedicinesSourceTaladegib (ENV-101)Idiopathic pulmonary fibrosis (IPF)November 3, 2025
aptaTargetsSourceApTOLLAcute ischemic stroke1 March, 2023
SpliSenseSourceSPL84Cystic fibrosis with the 3849+10Kb C>T CFTR mutationMarch 3, 2026

Estimated ~160 entries. If people reserve it, we'll try to compile it (we can't compile every list).

* No charge now. Purchase is optional.

Who holds EMA PRIME eligibility, and why it matters for partnering

PRIME (PRIority MEdicines) is the European Medicines Agency's voluntary support scheme for medicines that target an unmet medical need. Launched in 2016, it is the closest EU counterpart to the FDA's Breakthrough Therapy designation: a sponsor applies with non-clinical and early clinical data, the Scientific Advice Working Party and CHMP assess the request, and if the medicine is judged eligible the sponsor gets enhanced, earlier regulatory support and the prospect of accelerated assessment at the marketing authorisation stage.

For business development, licensing and investment teams, PRIME eligibility is a strong external signal. EMA grants it to a small fraction of requests, and only where early data suggest a meaningful benefit over existing options or a benefit where no treatment exists. Many holders are small and mid-sized biotechs that are actively looking for EU partners, manufacturing capacity and clinical sites.

What EMA publishes, and what it leaves out

EMA maintains a spreadsheet of medicines currently in PRIME (reference EMA/521657/2016) and a separate tab for medicines that left the scheme, either because a marketing authorisation application was submitted or because the product was withdrawn. Each row gives the active substance or company code, substance type, therapeutic area, indication, the type of data that supported the request, the type of applicant (SME, academic or other) and the date eligibility was granted.

What the EMA list does not give is the sponsor. A row such as NRTX-1001 or SPL84 has to be traced to the company through its own announcement, clinical trial registrations or the EMA SME register. That join is what turns the agency list into a target list.

How the PRIME process works

  1. Eligibility request. The sponsor submits a justification against the PRIME criteria on a published submission timetable aligned with CHMP meetings.
  2. Assessment. EMA's scientific committees evaluate whether the data show potential to address an unmet need, and CHMP adopts a recommendation, normally within about 40 days of the procedure start.
  3. Early support. Eligible sponsors receive a CHMP rapporteur, a kick-off meeting with a multidisciplinary EMA team, and iterative scientific advice at key development milestones.
  4. Accelerated assessment. At the marketing authorisation stage, PRIME products are expected to qualify for accelerated assessment (150 instead of 210 days, excluding clock stops).

Early entry routes for SMEs and academics

SMEs and academic applicants can request PRIME at the proof-of-principle stage, on the basis of compelling non-clinical data and tolerability data from first-in-human studies. Medicines granted eligibility this way are shown in italics on the EMA list. Other applicants need clinical exploratory data. EMA has also piloted further features for PRIME products, such as earlier dialogue on development plans, which sponsors sometimes describe in announcements as early PRIME support.

Where PRIME medicines concentrate

Pattern on the EMA listWhat it means for outreach
Advanced therapy medicinal products (gene and cell therapies) are the largest substance typeCDMOs with viral vector, cell processing and release-testing capacity have the most direct fit
Oncology, ophthalmology, neurology and metabolic disorders are the most frequent therapeutic areasLicensing teams can map PRIME holders against portfolio gaps by area
A large share of applicants are registered as SMEsSmaller sponsors are more likely to seek partners, regional rights deals or outsourced development
Products leave the current list when an application is filedThe previous-products tab flags sponsors approaching EU launch, relevant for commercial and market access services

PRIME versus FDA Breakthrough Therapy

The two programmes share intent but differ in practice. Breakthrough Therapy designation requires preliminary clinical evidence of substantial improvement on a clinically significant endpoint, while PRIME also admits SME and academic products on non-clinical data plus first-in-human tolerability. Many sponsors hold both, and EMA and FDA have published joint questions and answers on quality and GMP aspects of PRIME and Breakthrough applications. A sponsor that holds one but not the other is a useful signal of regulatory strategy and regional focus.

How to use a PRIME sponsor list

  • In-licensing and partnering: screen for SMEs with PRIME products in your therapeutic areas that do not yet have an EU commercial partner.
  • CRO and CDMO sales: prioritise sponsors whose products are advanced therapies or are close to filing, where manufacturing scale-up and pivotal trials are imminent.
  • Investment: combine PRIME eligibility date and applicant type to track which private biotechs have regulatory validation in both the EU and US.

EMA's list is the authoritative record of which medicines are or were in the scheme. Company announcements are the usual link between a product code and its sponsor, and should be checked against the EMA list, since some announcements describe related EMA support programmes rather than PRIME eligibility itself.

Frequently Asked Questions

Q.What is the difference between EMA PRIME and FDA Breakthrough Therapy designation?

Both give enhanced regulatory support to medicines addressing unmet needs. Breakthrough Therapy requires preliminary clinical evidence of substantial improvement, while PRIME also accepts SME and academic products on non-clinical data plus first-in-human tolerability. PRIME leads to expected eligibility for accelerated assessment in the EU, which shortens the standard 210-day review to 150 days.

Q.How long does EMA take to decide on a PRIME eligibility request?

Requests follow a published submission timetable tied to CHMP meetings, and the CHMP normally adopts its recommendation about 40 days after the procedure starts.

Q.What support does a medicine receive once it is eligible for PRIME?

The sponsor is assigned a CHMP rapporteur, holds a kick-off meeting with a multidisciplinary EMA team, and receives scientific advice at key development milestones, with the expectation of accelerated assessment when the marketing authorisation application is filed.

Q.Why does a medicine leave EMA's current PRIME list?

Products move off the current list when a marketing authorisation application is submitted or when the product is withdrawn from the scheme, for example after negative trial results. EMA keeps these on a separate tab of previous PRIME products.

Q.Does PRIME eligibility guarantee approval in the EU?

No. PRIME provides earlier dialogue and the prospect of accelerated assessment, but the marketing authorisation still depends on the full benefit-risk evaluation by the CHMP.

Q.Can I buy the list now?

Not yet. Sample rows are free. We try to compile lists that people reserve (we can't compile every list). If we do, we'll email everyone who reserved it a purchase link (buying is optional). If we don't, nothing happens and you're never charged.

Q.What does it cost?

Sample rows are free. A list is $49, paid only if we compile it and you decide to buy. There is no free trial or subscription.